Increased frequency of regulatory T cells in the peripheral blood of patients with endometrioid adenocarcinoma

Li,Li; Li,Yinghua; Yin,Zhuomin; Zhu,Jing; Yan,Dingding; Lou,Hanmei

doi:10.3892/ol.2019.10452

Increased frequency of regulatory T cells in the peripheral blood of patients with endometrioid adenocarcinoma

Authors:
- Li Li
- Yinghua Li
- Zhuomin Yin
- Jing Zhu
- Dingding Yan
- Hanmei Lou
View Affiliations

Affiliations: Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China
Published online on: June 7, 2019 https://doi.org/10.3892/ol.2019.10452
Pages: 1424-1430

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the frequency of cluster of differentiation (CD)4+CD25+CD127‑ regulatory T cells (Tregs) in the peripheral blood mononuclear cells (PBMCs) of patients with endometrioid adenocarcinoma (EA). A total of 82 female patients with EA were recruited. The PBMCs were flow cytometrically analyzed to determine the percentage of CD4+CD25+CD127‑ Tregs within the CD4+ T cell population. The associations between the prevalence of Tregs in PBMCs and defined clinical prognostic parameters were evaluated. To study the immunoregulatory capacity of Tregs, the level of specific cytokines were detected by ELISA, and the proliferation of cells was analyzed by incorporation of 3H‑thymidine. It was revealed that Treg/CD4+ ratio in the peripheral blood of patients with EA was 4.89±1.42%, significantly higher than Treg/CD4+ ratio in healthy women. No correlation was observed between Treg frequency and stage, grade of differentiation, menopausal status or age. CD4+CD25+CD127‑ Tregs secreted large amounts of IL‑10 but not IFN‑γ. The level of IL‑10 secreted by Tregs from patients with EA and healthy controls was not significantly different. In addition, there was no significant difference in the suppressive activity of Tregs in patients with EA compared with that of the healthy controls. These findings demonstrate that the increased frequency of immunosuppressive Tregs in patients with EA may be responsible for immune tolerance in endometrial cancer.

View Figures

View References

1	Li L, Wu J, Pu D, Zhao Y, Wan C, Sun L, Shen C, Sun W, Yuan Z, Shen Q, et al: Factors associated with the age of natural menopause and menopausal symptoms in Chinese women. Maturitas. 73:354–360. 2012. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Murali R, Soslow RA and Weigelt B: Classification of endometrial carcinoma: More than two types. Lancet Oncol. 15:e268–e278. 2014. View Article : Google Scholar : PubMed/NCBI
4	Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A and Oliver T; Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site, : Follow-up after primary therapy for endometrial cancer: A systematic review. Gynecol Oncol. 101:520–529. 2006. View Article : Google Scholar : PubMed/NCBI
5	Lajer H, Elnegaard S, Christensen RD, Ortoft G, Schledermann DE and Mogensen O: Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey. Acta Obstet Gynecol Scand. 91:976–982. 2012. View Article : Google Scholar : PubMed/NCBI
6	Vanderstraeten A, Tuyaerts S and Amant F: The immune system in the normal endometrium and implications for endometrial cancer development. J Reprod Immunol. 109:7–16. 2015. View Article : Google Scholar : PubMed/NCBI
7	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI
8	Sakaguchi S, Miyara M, Costantino CM and Hafler DA: FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 10:490–500. 2010. View Article : Google Scholar : PubMed/NCBI
9	Wing K and Sakaguchi S: Regulatory T cells exert checks and balances on selftolerance and autoimmunity. Nat Immunol. 11:7–13. 2010. View Article : Google Scholar : PubMed/NCBI
10	Shevach EM: Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 30:636–645. 2009. View Article : Google Scholar : PubMed/NCBI
11	Beyer M and Schultze JL: Regulatory T cells in cancer. Blood. 108:804–811. 2006. View Article : Google Scholar : PubMed/NCBI
12	Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L and Pisa P: CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 177:7398–7405. 2006. View Article : Google Scholar : PubMed/NCBI
13	Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, Salagianni ML, Orphanos G, Baxevanis CN, Rigatos G and Papamichail M: CD4+CD25+ Regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 13:2714–2721. 2007. View Article : Google Scholar : PubMed/NCBI
14	Hanagiri T, Shigematsu Y, Shinohara S, Takenaka M, Oka S, Chikaishi Y, Nagata Y, Iwata T, Uramoto H, So T and Tanaka F: Clinical significance of the frequency of regulatory T cells in regional lymph node lymphocytes as a prognostic factor for non-small-cell lung cancer. Lung Cancer. 81:475–479. 2013. View Article : Google Scholar : PubMed/NCBI
15	Sellitto A, Galizia G, De Fanis U, Lieto E, Zamboli A, Orditura M, De Vita F, Giunta R, Lucivero G and Romano C: Behavior of circulating CD4+CD25+Foxp3+ regulatory t cells in colon cancer patients undergoing surgery. J Clin Immunol. 31:1095–1104. 2011. View Article : Google Scholar : PubMed/NCBI
16	Wertel I, Surówka J, Polak G, Barczyński B, Bednarek W, Jakubowicz-Gil J, Bojarska-Junak A and Kotarski J: Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumour Biol. 36:4811–4817. 2015. View Article : Google Scholar : PubMed/NCBI
17	Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME Sakaguchi S and Houghton AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 200:771–782. 2004. View Article : Google Scholar : PubMed/NCBI
18	Chang WC, Li CH, Huang SC, Chang DY, Chou LY and Sheu BC: Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma. Cancer. 116:5777–5788. 2010. View Article : Google Scholar : PubMed/NCBI
19	Fattorossi A, Battaglia A, Ferrandina G, Buzzonetti A, Legge F, Salutari V and Scambia G: Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol Oncol. 92:106–115. 2004. View Article : Google Scholar : PubMed/NCBI
20	Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, Suzuki N, Tsuda H, Tsukazaki K and Aoki D: Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory t cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer. 21:1628–1634. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sawan S, Burt DJ, Stern PL, Holland C and Elkord E: Circulating regulatory T cells in endometrial cancer: A role for age and menopausal status. Immunol Invest. 40:62–75. 2011. View Article : Google Scholar : PubMed/NCBI
22	Creasman W: Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009. View Article : Google Scholar : PubMed/NCBI
23	Kong A, Johnson N, Kitchener HC and Lawrie TA: Adjuvant radiotherapy for stage I endometrial cancer: An updated cochrane systematic review and meta-analysis. J Natl Cancer Inst. 104:1625–1634. 2012. View Article : Google Scholar : PubMed/NCBI
24	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
25	Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, et al: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 203:1701–1711. 2006. View Article : Google Scholar : PubMed/NCBI
26	Sawan S, Burt DJ, Stern PL, Holland C and Elkord E: Circulating regulatory T cells in endometrial cancer: A role for age and menopausal status. Immunol Invest. 40:62–75. 2011. View Article : Google Scholar : PubMed/NCBI
27	Morice P, Leary A, Creutzberg C, Abu-Rustum N and Darai E: Endometrial cancer. Lancet. 387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI
28	Tsaknaridis L, Spencer L, Culbertson N, Hicks K, LaTocha D, Chou YK, Whitham RH, Bakke A, Jones RE, Offner H, et al: Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res. 74:296–308. 2003. View Article : Google Scholar : PubMed/NCBI
29	Santner-Nanan B, Seddiki N, Zhu E, Quent V, Kelleher A, Fazekas de St Groth B and Nanan R: Accelerated age-dependent transition of human regulatory T cells to effector memory phenotype. Int Immunol. 20:375–383. 2008. View Article : Google Scholar : PubMed/NCBI
30	Dejaco C, Duftner C and Schirmer M: Are regulatory T-cells linked with aging? Exper Gerontol. 41:339–345. 2006. View Article : Google Scholar
31	Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA and Robbins PF: Levels of peripheral CD4(+)Foxp3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 119:5688–5696. 2012. View Article : Google Scholar : PubMed/NCBI
32	Arruvito L, Sanz M, Banham AH and Fainboim L: Expansion of CD4+CD25+ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: Implications for human reproduction. J Immunol. 178:2572–2578. 2007. View Article : Google Scholar : PubMed/NCBI
33	El-Hamarneh T, Hey-Cunningham AJ, Berbic M, Al-Jefout M, Fraser IS and Black K: Cellular immune environment in endometrial polyps. Fertil Steril. 100:1364–1372. 2013. View Article : Google Scholar : PubMed/NCBI
34	Murphy KM, Ouyang W, Szabo SJ, Jacobson NG, Guler ML, Gorham JD, Gubler U and Murphy TL: T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Curr Top Microbiol Immunol. 238:13–26. 1999.PubMed/NCBI
35	Caretto D, Katzman SD, Villarino AV, Gallo E and Abbas AK: Cutting edge: The Th1 response inhibits the generation of peripheral regulatory T cells. J Immunol. 184:30–34. 2010. View Article : Google Scholar : PubMed/NCBI
36	Asseman C, Mauze S, Leach MW, Coffman RL and Powrie F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 190:995–1004. 1999. View Article : Google Scholar : PubMed/NCBI
37	Belkaid Y, Piccirillo CA, Mendez S, Shevach EM and Sacks DL: CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 420:502–507. 2002. View Article : Google Scholar : PubMed/NCBI
38	Loser K, Apelt J, Voskort M, Mohaupt M, Balkow S, Schwarz T, Grabbe S and Beissert S: IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol. 179:365–371. 2007. View Article : Google Scholar : PubMed/NCBI
39	Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S and Katsanis E: Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother. 56:48–59. 2007. View Article : Google Scholar : PubMed/NCBI
40	Vieweg J, Su Z, Dahm P and Kusmartsev S: Reversal of tumor-mediated immunosuppression. Clin Cancer Res. 13:727s–732s. 2007. View Article : Google Scholar : PubMed/NCBI
41	Nishikawa H and Sakaguchi S: Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 27:1–7. 2014. View Article : Google Scholar : PubMed/NCBI